Table 1.
Main patients' and haplo‐HSCT characteristics
| Characteristics | HLA‐haploidentical (n = 70) |
|---|---|
| Age, median, in years (range) | 45 (19–72) |
| Diagnosis, n (%) | |
| Hodgkin's lymphoma | 35 (50) |
| Non‐Hodgkin's lymphoma | 20 (29) |
| Multiple myeloma | 2 (3) |
| Acute leukemia | 11 (15) |
| Chronic lymphoid leukemia | 2 (3) |
| CMV serostatus, n (%) | |
| Donor (−)/Recipient (−) | 5 (7) |
| Donor (−)/Recipient (+) | 11 (15) |
| Donor (+)/Recipient (−) | 6 (8) |
| Donor (+)/Recipient (+) | 48 (70) |
| Graft type, n (%) | |
| BM | 66 (94) |
| PBSC | 4 (6) |
| Time to diagnosis—haplo‐HSCT median, in months (range) | 26 (3–195) |
| Disease status at haplo‐HSCT, n (%) | |
| CR | 38 (54) |
| PR | 19 (27) |
| SD | 3 (4) |
| PD | 10 (15) |
| Conditioning regimen, n (%) | |
| NMA | 48 (68) |
| RIC | 16 (23) |
| MA | 6 (9) |
| Year of haplo‐HSCT, median (range) | 2012 (2009–2014) |
Haplo‐HSCT, haploidentical hematopoietic stem cell transplantation; HLA, human leukocyte antigen; CMV, cytomegalovirus; BM, bone marrow; PBSC, peripheral blood stem cells; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; NMA, non‐myeloablative; RIC, reduced‐intensity conditioning; MA, myeloablative.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.